Lamuna 30

Desogestrel/Ethinylestradiol, the active ingredients in Lamuna 30, are a combined oral contraceptive presented as a tablet for oral use. It prevents pregnancy in women of reproductive age by providing reliable hormonal contraception. It is indicated for contraception and may also help regulate menstrual cycles, offering additional benefits for cycle control.

GNH USA supplies Lamuna 30 as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved products to a global network of healthcare providers.

Lamuna 30, a combined oral contraceptive, is used within the hormonal contraception pathway to prevent unintended pregnancy.

- Prevention of pregnancy: provides reliable contraceptive protection when taken daily as directed. - Regulation of menstrual cycles: helps achieve more predictable bleeding patterns and may reduce menstrual discomfort. - Management of dysmenorrhea: can lessen menstrual pain associated with primary dysmenorrhea.

Lamuna 30 may be associated with a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Nausea - Breast tenderness - Headache - Weight change - Mood changes - Spotting between periods

Serious or Rare Side Effects: - Venous thromboembolism - Arterial thrombosis - Hypertension - Severe allergic reaction (anaphylaxis) - Liver dysfunction - Visual disturbances

Before prescribing Lamuna 30, clinicians should consider several precautionary measures to ensure safe use.

- Cardiovascular risk assessment: evaluate history of thromboembolic events, myocardial infarction or stroke. - Smoking status: avoid use in women over 35 who smoke due to increased clot risk. - Hepatic function: use with caution in patients with liver disease or impaired hepatic metabolism. - Blood pressure monitoring: the estrogen component may elevate blood pressure; monitor regularly. - Concomitant medication review: assess for drugs that induce hepatic enzymes which may reduce efficacy. - Store at ambient temperature: keep tablets in the original packaging, protect from moisture and light.

Lamuna 30 can interact with other medicines, affecting its contraceptive effectiveness or safety profile.

Major Interactions (Avoid): - Potent enzyme inducers (e.g., rifampicin, carbamazepine, phenytoin): markedly reduce plasma levels of both hormones, risking contraceptive failure. - Anticoagulants (e.g., warfarin): combined use may increase bleeding risk and require closer coagulation monitoring.

Moderate Interactions (Monitor Closely): - Certain antibiotics (e.g., tetracycline, metronidazole): may slightly lower hormone concentrations. - Herbal supplements (e.g., St. John’s wort): can decrease effectiveness through enzyme induction. - Antiepileptic drugs (e.g., valproate): may modestly reduce contraceptive reliability.